Retention Rate and Illicit Opioid Use During Methadone Maintenance Interventions: a Meta-analysis
Overview
Affiliations
The efficacy of methadone maintenance in opioid addiction was assessed in terms of programme retention rate and reduction of illicit opioid use by means of a meta-analysis of randomised, controlled and double blind clinical trials. The results were compared with interventions using buprenorphine and levo-acetylmethadol (LAAM). Trials were identified from the PubMed database from 1966 to December 1999 using the major medical subject headings 'methadone' and 'randomised controlled trial'. Data for a total of 1944 opioid-dependent patients from 13 studies were analysed. Sixty-four percent of patients received methadone, administered either as fixed or adjusted doses. Thus, 890 patients received > or = 50 mg/day (high dose group) and 392 were given < 50 mg/day (low dose group). Of 662 controls, 131 received placebo, 350 buprenorphine (265 at doses > or = 8 mg/day and 85 at doses < 8 mg/day) and 181 LAAM. High doses of methadone were more effective than low doses in the reduction of illicit opioid use (odds ratio [OR] 1.72, 95% confidence interval [CI] 1.26--2.36). High doses of methadone were significantly more effective than low doses of buprenorphine (< 8 mg/day) for retention rates and illicit opioid use, but similar to high doses of buprenorphine (> or = 8 mg/day) for both parameters. Patients treated with LAAM had more risk of failure of retention than those receiving high doses of methadone (OR 1.92, 95% CI 1.32--2.78). It is proposed that in agonist-maintenance programmes, oral methadone at doses of 50 mg/day or higher is the drug of choice for opioid dependence.
Bouthillier A, Bastien G, McAnulty C, Bakouni H, Le Foll B, Socias M Harm Reduct J. 2025; 22(1):14.
PMID: 39923043 PMC: 11806552. DOI: 10.1186/s12954-025-01157-4.
Earnshaw V, Sepucha K, Laurenceau J, Subramanian S, Hill E, Wallace J J Subst Use Addict Treat. 2024; 160:209291.
PMID: 38272118 PMC: 11060902. DOI: 10.1016/j.josat.2024.209291.
Williams A, Krawczyk N, Hu M, Harpel L, Aydinoglo N, Cerda M Lancet Reg Health Am. 2023; 28:100636.
PMID: 38152421 PMC: 10751716. DOI: 10.1016/j.lana.2023.100636.
Impact of California Statute on Naloxone Availability and Opioid Overdose Rates.
Gallant T, Gilbert A, Zargham S, Lorenzo M, Puglisi J, Nicholas Z AJPM Focus. 2023; 2(3):100112.
PMID: 37790675 PMC: 10546523. DOI: 10.1016/j.focus.2023.100112.
Bardwell G, Ivsins A, Mansoor M, Nolan S, Kerr T CMAJ. 2023; 195(19):E668-E676.
PMID: 37188370 PMC: 10185363. DOI: 10.1503/cmaj.221550.